Morgan Stanley Can Fite Bio Pharma Ltd. Transaction History

Morgan Stanley

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.6 - $8.94 $9,300 - $138,570	-15,500 Reduced 4.84%	304,675 $185,000
Q3 2022 Nov 14, 2022	SELL	$0.74 - $7.9 $13,394 - $142,990	-18,100 Reduced 5.35%	320,175 $247,000
Q2 2022 Oct 27, 2022	BUY	$0.83 - $1.24 $28,303 - $42,284	34,100 Added 11.21%	338,275 $311,000
Q2 2022 Aug 15, 2022	BUY	$0.83 - $1.24 $28,303 - $42,284	34,100 Added 11.21%	338,275 $311,000
Q1 2022 Oct 27, 2022	SELL	$0.94 - $1.45 $32,054 - $49,445	-34,100 Reduced 10.08%	304,175 $377,000
Q1 2022 May 13, 2022	BUY	$0.94 - $1.45 $61,776 - $95,294	65,720 Added 27.56%	304,175 $377,000
Q4 2021 Feb 14, 2022	BUY	$0.98 - $2.15 $40,944 - $89,827	41,780 Added 21.24%	238,455 $308,000
Q3 2021 Nov 15, 2021	BUY	$1.65 - $2.34 $324,513 - $460,219	196,675 New	196,675 $326,000

1.1K

Ticker CANF
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 27,191,500
Market Cap $44.6M
Description
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinic...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.